A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes inFlavivirus‐Naive Adults
Open Access
- 1 February 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 201 (3) , 370-377
- https://doi.org/10.1086/649916
Abstract
Background. Sanofi Pasteur has developed a tetravalent dengue vaccine (TDV) against the world's most common arbovirus infection.Methods. We assessedKeywords
This publication has 0 references indexed in Scilit: